A supracilliary micro-stent, when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma, according to researchers in Germany and the US.
A supracilliary micro-stent (CyPass, Transcend Medical, Menlo Park, California, USA), when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma (OAG), according to researchers in Germany and the US.
The researchers conducted a multicentre, prospective, consecutive case series of 136 eyes in 136 subjects with OAG. All of the eyes required cataract surgery, and underwent a combined phacoemulsification with intraocular lens insertion and implantation of the micro-stent. The researchers examined 24-month postoperative data.
At baseline, the subjects were divided into two cohorts: Cohort 1 (51 patients) had uncontrolled IOP of greater than 21 mmHg; Cohort 2 (85 patients) had controlled IOP of less than 21 mmHg. All of the patients were receiving glaucoma medications, which were discontinued postoperatively.
Eighty-two patients remained in the study through the 24-month follow up. After 24 months, the mean IOP in Cohort 1 (23 patients) was 15.8 ± 3.8 mmHg (a reduction of 37% ± 19%). The mean IOP decrease from baseline in Cohort 1 was statistically significant (P P = 0.0188) and 12 (P = 0.0356) in Cohort 2.
No sight-threatening adverse events occurred, and there was a statistically significant mean decrease of glaucoma medication use in both cohorts. To read an abstract of the study published in Klinische Monatsblätter für Augenheilkunde, click here.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.